

discrepancy suggests the efficacy of BPHC's past investments in FY 2011 and FY 2012 that supported health centers funded before FY 2012 achieve patient centered medical home recognition. The FY 2016 Health Center Program Patient Centered Medical Home Supplement is the first funding not tied to capital improvements that BPHC has offered to support health centers' evolution to patient centered medical homes since FY 2012.

FOR FURTHER INFORMATION CONTACT: Olivia Shockey, Expansion Division Director, Office of Policy and Program Development, Bureau of Primary Health Care, Health Resources and Services Administration at 301-443-9282 or oshockey@hrsa.gov.

Dated: May 5, 2016.

James Macrae,
Acting Administrator.

[FR Doc. 2016-11413 Filed 5-12-16; 8:45 am]

BILLING CODE 4165-15-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case:

John G. Pastorino, Ph.D., Rowan University School of Osteopathic Medicine: Based on an assessment conducted by Rowan University School of Osteopathic Medicine (RUSOM), the Respondent's desire to conclude the matter, and analysis conducted by ORI in its oversight review, ORI found that Dr. John G. Pastorino, Associate Professor, Department of Molecular Biology, RUSOM, engaged in research misconduct in research supported by National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health (NIH), grant R01 AA012897 and National Cancer Institute (NCI), NIH, grant R01 CA118356.

ORI found that Respondent engaged in research misconduct by intentionally falsifying and/or fabricating data reported in the following eight (8) published papers, one (1) unpublished manuscript, and one (1) NIH grant application:

- *J. Cell. Sci.* 123:894–902, 2010 (hereafter referred to as “*J. Cell. Sci.* 2010a”)

- *J. Cell. Sci.* 123:4117–4127, 2010 (hereafter referred to as “*J. Cell. Sci.* 2010b”)
- *J. Cell. Sci.* 125:2995–3003, 2012 (hereafter referred to as “*J. Cell. Sci.* 2012”)
- *J. Cell. Sci.* 126:274–288, 2013 (hereafter referred to as “*J. Cell. Sci.* 2013”)
- *J. Cell. Sci.* 127:896–907, 2014 (hereafter referred to as “*J. Cell. Sci.* 2014”)
- *Biol. Open.* 1–11:10;bio.014712, 2015 (hereafter referred to as “*Biol. Open.* 2015”)
- *BioChim Biophys Acta.* 1827:38–49, 2013 (hereafter referred to as “*BioChim Biophys Acta.* 2013”)
- *J. Biol. Chem.* 289:26213–26225, 2014 (hereafter referred to as “*J. Biol. Chem.* 2014”)
- *J. Cell. Science*, Submitted manuscript, 2015 (hereafter referred to as “*J. Cell. Sci.* manuscript 2015”)
- R01 HL132672–01, “Regulation by Sirtuin-3 and Mitoneet of the Permeability Transition Pore in Heart during Ischemia/Reperfusion Injury,” John Pastorino, Ph.D., Principal Investigator ORI found that Dr. Pastorino falsified and/or fabricated Western blot data for mitochondrial function related to cell/tissue injury, in fifty-eight (58) blot panels included in forty-two (42) figures in eight (8) publications, one (1) unpublished manuscript, and one (1) grant application. In the absence of valid Western blot images, the Respondent fabricated and/or falsified quantitative data in associated bar graphs, statistical analyses presented in figure legends, and related text.

Specifically, ORI found that Respondent duplicated images, or trimmed and/or manipulated blot images from unrelated sources to obscure their origin, and relabeled them to represent different experimental results in:

- Figures 2A, 2C, 3B, 5A, 7B, and 8A in *J. Cell. Sci.* 2010a
- Figures 2B, 5A, 6A, and 6B in *J. Cell. Sci.* 2010b
- Figures 1A, 2A, 2B, 4C, 5A, 5B, 6A, 7A, 7B, and 7C in *J. Cell. Sci.* 2012
- Figures 4F, 5H, and 6A in *J. Cell. Sci.* 2013
- Figures 1B, 2B, 2C, 3A, 3B, and 4D in *J. Cell. Sci.* 2014
- Figures 3A and 6B in *Biol. Open* 2015
- Figure 2A in *BioChim Biophys Acta.* 2013
- Figures 1B, 3A, 4D, 5E, and 6C in *J. Biol. Chem.* 2014
- Figure 3A in *J. Cell. Sci.* manuscript 2015
- Figures 3, 8A, 12, and 13A in R01 HL132672–01 NIH grant application

Dr. Pastorino has entered into a Voluntary Exclusion Agreement (Agreement) and has voluntarily agreed for a period of five (5) years, beginning on April 27, 2016:

(1) To exclude himself from any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States Government referred to as “covered transactions” pursuant to HHS’ Implementation (2 CFR part 376 *et seq.*) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively the “Debarment Regulations”);

(2) that he will neither apply for nor permit his name to be used on any application, proposal, or other request for funds to the United States Government or any of its agencies, as defined in the Debarment Regulations; Respondent will further ensure that during the period of the voluntary exclusion, he will neither receive nor be supported by funds of the United States Government and its agencies made available through grants, subgrants, cooperative agreements, contracts, or subcontracts, as discussed in the Debarment Regulations; and

(3) to exclude himself from serving in any advisory capacity to the U.S. Public Health Service (PHS) including, but not limited to, service on any PHS advisory committee, board, and/or peer review committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453–8200.

Kathryn Partin,

Director, Office of Research Integrity.

[FR Doc. 2016-11317 Filed 5-12-16; 8:45 am]

BILLING CODE 4150-31-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Request for Information for Developing the National Cancer Moonshot Initiative

SUMMARY: This Request for Information (RFI) describes ways in which the cancer research community and public can provide new ideas and comment on proceedings of the National Cancer Advisory Board (NCAB) Blue Ribbon Panel under the umbrella of the National Cancer Moonshot Initiative.

DATES: Responses should be submitted to the National Cancer Institute (NCI), National Institutes of Health (NIH) on or before 5:00 p.m. EST on July 1, 2016.

ADDRESSES: Electronic responses are preferred and should be addressed or submitted to either: (1) The online platform, Cancer Research Ideas, at <https://cancerresearchideas.cancer.gov/>; or (2) email to cancerresearch@nih.gov. Non-electronic responses will also be accepted by calling the NCI Cancer Information Service at 1-800-422-6237 or by mail to Blue Ribbon Panel, National Cancer Moonshot Initiative, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892-9760.

FOR FURTHER INFORMATION: Questions about this request for information should be directed to Kelli Marciel, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD 20892-9760, Kelli.Marciel@nih.gov, 301-594-3330.

SUPPLEMENTARY INFORMATION: During his State of the Union address on January 12, 2016, President Barack Obama announced the establishment of a new National Cancer Moonshot Initiative to accelerate cancer research. The initiative, led by Vice President Joe Biden, aims to make more therapies available to more patients, while also improving our ability to prevent cancer and detect it at an early stage. Additional details of the National Cancer Moonshot Initiative are available at <http://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative>.

The White House and Vice President Biden have named a Task Force of 13 heads of federal agencies and offices who will advise the administration on research priorities. To ensure that the National Cancer Moonshot Initiative's goals and approaches are grounded in the best science, President Obama directed the Moonshot Task Force to consult with external experts, including the presidentially appointed National Cancer Advisory Board (NCAB). A Blue Ribbon Panel of experts has been established as a working group of the NCAB that will assist the board in providing this advice.

The Blue Ribbon Panel is composed of leading experts from a broad range of scientific areas, including biology, immunology, genomics, diagnostics, bioinformatics, and cancer prevention and treatment. Members also include investigators with expertise in clinical trials and cancer health disparities. In addition to researchers, the panel membership also includes clinicians and nurses, and representatives of cancer advocacy organizations and the pharmaceutical and biotechnology industries.

The Blue Ribbon Panel will focus on identifying scientific opportunities in

cancer research that could produce major advances with additional emphasis and funding, and propose ways to overcome barriers to pursuing these opportunities.

Community input is critical to the success of the National Cancer Moonshot Initiative. Indeed, the success of the initiative will depend on breaking down silos and encouraging everyone with an interest in fighting cancer to work together, share information, and collaborate on solutions. To enable the Blue Ribbon Panel to consider a wide range of input from researchers, scientists, physicians, advocates, students, data scientists, and members of the public, anyone with a scientific idea or suggestion for addressing cancer research challenges can contribute by visiting <https://cancerresearchideas.cancer.gov>.

Input is sought in the following areas:

- Expanding clinical trials
- Enhanced data sharing
- Cancer immunology and prevention
- Implementation sciences
- Pediatric cancer
- Precision, prevention and early detection
- Tumor evolution and progression

This RFI is for planning purposes only and should not be construed as a solicitation for applications or proposals, or as an obligation in any way on the part of the United States Federal government. The Federal government will not pay for the preparation of any information submitted or for the government's use. Additionally, the government cannot guarantee the confidentiality of the information provided.

Dated: May 5, 2016.

Dinah Singer,

Acting Deputy Director, National Cancer Institute.

[FR Doc. 2016-11283 Filed 5-12-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Alcohol Abuse and Alcoholism; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and

the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Alcohol Abuse and Alcoholism Special Emphasis Panel; RFA Review and Reverse Site Visit of INIA NEUROIMMUNE Consortium.

Date: June 24, 2016.

Time: 8:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Marriott New Orleans, 614 Canal Street, New Orleans, LA 70130.

Contact Person: Beata Buzas, Ph.D., Scientific Review Officer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, 5635 Fishers Lane, Rm. 2081, Rockville, MD 20852, 301-443-0800, bbuzas@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.271, Alcohol Research Career Development Awards for Scientists and Clinicians; 93.272, Alcohol National Research Service Awards for Research Training; 93.273, Alcohol Research Programs; 93.891, Alcohol Research Center Grants; 93.701, ARRA Related Biomedical Research and Research Support Awards., National Institutes of Health, HHS)

Dated: May 9, 2016.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2016-11257 Filed 5-12-16; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings.

The meetings will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose